Bio-Techne Corp Surpasses Expectations in Q4 FY2026 Financials Amid Merck Acquisition

TECH Bio-Techne Corp has reported its Q4 FY2026 financial results, showing organic revenue growth of 3% and GAAP EPS at $0.35. The company also announced an acquisition by Merck KGaA for $73 per share. Segment margins improved due to divestitures and profitability initiatives.

The company's adjusted EPS came in at $0.52, a figure that represents the company's core earnings without one-time items. This improvement in segment margins is attributed to the company's strategic moves, including divestitures and profitability initiatives.

The acquisition by Merck KGaA is expected to bring significant value to both companies, with Merck looking to expand its presence in the life science market.